• Kendall

Interferon Gamma Trial in Phase 3!

Horizon Pharma, a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced it has initiated the Phase 3 Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study ("STEADFAST") of ACTIMMUNE (interferon gamma-1b) for the treatment of people with Friedreich's Ataxia (FA), a degenerative neuro-muscular disorder.

"As a rare disease with no currently approved treatments, Friedreich's Ataxia represents an area of significant unmet medical need," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma. "The Phase 3 study represents a significant next step in evaluating ACTIMMUNE in this population, which is approximately four thousand people in the United States. We look forward to continuing to work with the FDA with the goal of providing a potential treatment option to the FA community."

To read more about the STEADFAST trial and Horizon Pharma, please see the full press release here: http://curefa.org/_pdf/HZNPnews150605.pdf

25 views0 comments

Recent Posts

See All

Choosing To Trust The One Who Holds Your Future

I am the "Blog Boss" for the fantastic ministry, Fearless Mom. We let moms share their unique perspectives in hopes of encouraging other moms, world-wide. I was featured on the blog and I wanted to sh

Taking Another Friedreich’s Ataxia Setback in Stride

I am a freelance columnist for Friedreich's Ataxia News. I was recently published on my column, My Darling Disability, and I wanted to share it here, too. You can either read it by following this link